Sibutramine and the management of obesity

Bibliography

• FOREYT JP, GOODRICK GK: The ultimate triumph of obesity. Lancet (1995) 346:134–135.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI). Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity: the evidence report. US Government Press, Washington DC (1998).
   Google Scholar
• •An extensive review of the empirical base for all obesity treatments.
   Google Scholar
• ALLISON DB, FONTAINE KR, MANS ON JE, STEVENS J, VANTALLIE TB: Annual deaths attributable to obesity in the United States. JA/VIA (1999) 282:1530–1538.
   Google Scholar
• COLDITZ GA: Economic costs of obesity and inactivity. Med. Sci. Sports Exerc. (1999) 31:S663–S667.
   PubMed Web of Science ®Google Scholar
• WOLF AM, COLDITZ GA:Current estimates of the economic cost ofobesity in the United States. Obes. Res. (1998) 6:97–106.
   PubMedGoogle Scholar
• FLEGAL KM, CARROLL MD, OGDEN CL, JOHNSON CL: Prevalence and trends in obesity among US adults, 1999-2000. JAMA (2002) 288: 1723-1727.
   Google Scholar
• YANOVSKI SZ, YANOVSKI JA: Drug therapy: obesity. N Engl. I Med. (2002) 346:591–602.
   PubMed Web of Science ®Google Scholar
• POSTON WSC, FOREYT JP:Successful management of the obese patient. Am. Fam. Physician (2000) 61:3615–3622.
   PubMedGoogle Scholar
• LUQUE CA, REY JA: The discovery and status of sibutramine as an anti-obesity drug. Eur. Pharmacol (2002) 440:119–128.
   PubMed Web of Science ®Google Scholar
• STAFFORD RS, RADLEY DC: National trends in antiobesity medication use. Arch. Intern. Med. (2003) 163:1046–1050.
   PubMedGoogle Scholar
• HEAL DJ, ASPLEY S, PROW MR, JACKSON HC, MARTIN KF,CHEETHAM SC: Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine. Int. .1. Obes. Reim. Metab. Disord. (1998) 22\(Suppl. 1):518–528.
   Google Scholar
• •An excellent review of the history and pharmacology of sibutramine.
   Google Scholar
• VAN GAAL LF, WAUTERS MA, PEIFFER FW, DE LEEUW IH: Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction? Int. .1. Obes. Reim. Metab. Disord. (1998)22 (Suppl. 1):538–540.
   Google Scholar
• RYAN DH: The role of sibutramine in the clinical management of obesity.In: Progress in Obesity Research: 9. Medeiros-Neto G, Halpern A, Bouchard C (Eds), John Libby Eurotext, Montrouge, France (2003):1051–1057.
   Google Scholar
• STOCK MJ: Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int. .1. Obes. Reim. Metab. Disord. (1997) 21\(Suppl. 1):525–529.
   Google Scholar
• CHAPELOT D MARMONIER C, THOMAS F, HANOTIN C:Modalities of the food intake-reducing effect of sibutramine in humans. Physiol Behav. (2000) 68:299–308.
   PubMedGoogle Scholar
• ROLLS BJ, SHIDE DJ, THORWART ML, ULBRECHT JS: Sibutramine reduces food intake in non-dieting women with obesity. Obes. Res. (1998) 6:1–11.
   PubMedGoogle Scholar
• HANSEN DL, TOUBRO S, STOCK MJ, MACDONALD IA, ASTRUP A: Thermogenic effects of sibutramine in humans. Am. I Clin. Num. (1998) 68:1180–1186.
   PubMed Web of Science ®Google Scholar
• HANSEN DL, TOUBRO S, STOCK MJ, MACDONALD IA, ASTRUP A:The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int. .1. Obes. Reim. Metab. Disord. (1999) 23:1016–1024.
   Google Scholar
• SEAGLE HM, BESSESEN DH, HILL JO:Effects of sibutramine on resting metabolic rate and weight loss in overweight women.Obes. Res. (1998) 6:115–121.
   PubMedGoogle Scholar
• STARLING RD, LIU X, SULLIVAN DH: Influence of sibutramine on energy expenditure in African American women. Obes. Res. (2001) 9:251–256.
   PubMedGoogle Scholar
• WALSH KM, LEEN E, LEAN ME: The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females. Int. .1. Obes. Relat. Metab. Disord. (1999) 23:1009–1015.
   PubMed Web of Science ®Google Scholar
• SMITH IG, GOULDER MA; on behalf of the Members of the Sibutramine Clinical Study 1047 Team: randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.Fam. Pract. (2001) 50:505–512.
   Google Scholar
• WIRTH A, KRAUSE J: Long-term weight loss with sibutramine: a randomized controlled trial. JA/VIA (2001) 286:1331–1339.
   Google Scholar
• FOREYT JP, POSTON WSC:Building better compliance: factors and methods common to achieving a healthy lifestyle. In: Drugs Affecting Lipid Metabolism: Risk Factors and Future Directions. Gotto AM, Paoletti R, Smith LC, Catapano AL, Jackson AS (Eds), Kluwer Academic Publishers, Dordrecht, The Netherlands (1996):489–496.
   Google Scholar
• APFELBAUM M, VAGUE P, ZIEGLER 0, HANOTIN C, THOMAS F, LEUTENNEGGER E: Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of efficacy and tolerability of sibutramine. Am.' Med. (1999) 106:179–184.
   PubMed Web of Science ®Google Scholar
• JAMES WPT, ASTRUP A, FINER N et al.: Effect of sibutramine on weight maintenance after weight loss: a randomized trial. Lancet (2000) 356:2119–2125.
   PubMedGoogle Scholar
• ••Prospective, randomised, controlled,mutlti-centre trial of sibutramine.
   Google Scholar
• VAN BAAK MA, VAN MILE, ASTRUP AV et al. STORM STUDY GROUP: Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and
   Google Scholar
• ••Maintenance (STORM trial). Am.j Clin. Num. (2003) 78:209–214.
   Google Scholar
• HANSEN DL, ASTRUP A, TOUBRO S et al.: Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Int. J. Obes. Relat. Metab. Disord. (2001) 25:496–501.
   PubMed Web of Science ®Google Scholar
• HADDOCK CK, POSTON WSC, DILL PL, FOREYT JP, ERICSSON M: Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int. .1 Obes. Relat. Metab. Disord. (2002) 26:262–273.
   PubMedGoogle Scholar
• ••A large obesity pharmacotherapy meta-analysis of 108 randomised, controlled trials.
   Google Scholar
• KIM SH, LEE YM, JEE SH, NAM CM: Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes. Res. (2003) 11:1116–1123.
   PubMedGoogle Scholar
• O'MEARA S, RIEMSMA R, SHIRRAN L, MATHER L, TER RIET G: The clinical effectiveness of sibutramine in the management of obesity: a technology assessment. Health Technol Assess. (2002) 6:1–97.
   PubMedGoogle Scholar
• PADWAL R, LI SK, LAU DCW: Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int. J. Obes. Relat. Metab. Disord. (2003) 27:1437–1446.
   PubMed Web of Science ®Google Scholar
• ••An excellent meta-analysis of long-termobesity pharmacotherapy studies.
   Google Scholar
• KREJS GJ: Metabolic benefits associated with sibutramine therapy. Int. J. Obes. Relat. Metab. Disord. (2002) 26\(Suppl. 4):S34–S37.
   Google Scholar
• •A review of the impact of sibutramine on visceral fat, diabetes parameters, and lipids.
   Google Scholar
• FORD ES, GILES WH, DIETZ WH: The prevalence of metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. JAMA (2002) 287:356–359.
   Google Scholar
• HAZENBERG BP: Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology (2000) 94:152–158.
   PubMed Web of Science ®Google Scholar
• MCMAHON FG, WEINSTEIN SP, ROWE E, ERNST KR, JOHNSON F, FUJIOKA K: Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled withangiotensin-converting enzyme inhibitors. J. Hum. Hypertens. (2002) 16:5–11.
   PubMed Web of Science ®Google Scholar
• SRAMEK JJ, LEIBOWITZ MT, WEINSTEIN SP et al.: Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. Hum. Hypertens. (2002) 16:13–19.
   PubMed Web of Science ®Google Scholar
• SHARMA AM: Sibutramine in overweight/obese hypertensive patients. Int. J. Obes. Relat. Metab. Disord. (2001) 25(Suppl 4):520–523.
   Google Scholar
• NARKIEWICZ K: Sibutramine and its cardiovascular profile. Int. .1 Obes. Relat. Metab. Disord. (2002)26\(Suppl. 4):S38–S41.
   Google Scholar
• •A review of the effect of sibutramine on blood pressure and heart rate.
   Google Scholar
• ZANNAD F, GILLE B,GRENTZINGER A et al.:Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am. Heart J. (2002) 144:508–515.
   Google Scholar
• DUJOVNE CA, ZAVORAL JH, ROWE E, MENDEL CM: Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia. Am. Heart' (2001) 142:489–497.
   PubMed Web of Science ®Google Scholar
• FINER N, BLOOM SR, FROST GS, BANKS LM, GRIFFITHS J:Sibutramine is effective for weight loss and diabetic control in obesity with Type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes. Metab. (2000) 2:105–112.
   PubMed Web of Science ®Google Scholar
• FUJIOKA K, SEATON TB, ROWE E et al: Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with Type 2 diabetes mellitus. Diabetes Obes. Metab. (2000) 2:175–187.
   PubMed Web of Science ®Google Scholar
• GOKCEL A, KARAKOSE H, ERTORER EM, TANACI N, TUTNCU NB, GUVENER N: Effects of sibutramine in obese female subjects with Type 2 diabetes and poor blood glucose control. Diabetes Care (2001) 24: 1957-1960.
   Google Scholar
• SERRANO-RIOS M, MELCHIONDA N, MORENO-CARRETERO E:Role of sibutramine in the treatment of obese Type 2 diabetic patients receivingsulphonylurea therapy. Diabet. Med. (2002) 19:119–124.
   PubMed Web of Science ®Google Scholar
• MCNULTY SJ, UR E, WILLIAMS G: A randomized trial of sibutramine in the management of obese Type 2 diabetic patients treated with metformin. Diabetes Care (2003) 26:125–131.
   PubMed Web of Science ®Google Scholar
• REDMON JB, RAATZ SK, RECK KP et al.: One-year outcome of a combination of weight loss therapies for subjects with Type 2 diabetes: a randomized trial. Diabetes Care (2003) 26:2505–2511.
   PubMed Web of Science ®Google Scholar
• MCMAHON FG, FUJIOKA K, SINGH BN et al.: Efficacy and safety of sibutramine in obese white and African American patients with hypertension. Arch. Intern. Med. (2000) 160:2185–2191.
   PubMed Web of Science ®Google Scholar
• MARTINEZ-CUELLAR GE, RUIZ AM, MONSALVE MCR, BERBER A: Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes. Res. (2000) 8:71–82.
   PubMedGoogle Scholar
• FANGHANEL G, CORTINAS L, SANCHEZ-REYES L, GOMEZ-SANTOS R, CAMPOS-FRANCO E, BERBER A: Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension. Adv. Ther (2003) 20:101–113.
   PubMed Web of Science ®Google Scholar
• BERKOWITZ RI, WADDEN TA, TERSHAKOVEC AM, CRONQUIST JL: Behavior therapy and sibutramine for the treatment of adolescent obesity.JAMA (2003) 289:1805–1812.
   Google Scholar
• •A randomised, controlled trial of sibutramine in adolescents.
   Google Scholar
• APPOLINARIO JC, GOD OY-MATOSA,FONTENELLE LF et al.: An open-label trial of sibutramine in obese patients with binge-eating disorder. J Clin. Psychiatry (2002) 63:28–30.
   Google Scholar
• APPOLINARIO JC, BACALTCHUK J, SICHIERI R et al.: A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder. Arch. Gen. Psychiatry (2003) 60:1109–1116.
   PubMed Web of Science ®Google Scholar
• MITCHELL JE, GOSNELL BA, ROERIG JL et al.: Effects of sibutramine on binge eating, hunger, and fullness in a laboratory human feeding paradigm. Obes. Res. (2003) 11:599–602.
   PubMedGoogle Scholar
• HANOTIN C, THOMAS F, JONES SP, LEUTENEGGER E, DROUIN P:Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int. Obes. Relat. Metab. Disord. (1998) 22:32–38.
   PubMed Web of Science ®Google Scholar
• LUSCOMBE GP, SLATER NA,LYONS MB, WYNEE RD,SCHEINBAUM ML, BUCKETT WR: Effects of radiolabelled-monoamine uptake in vitro of plasma taken from healthy volunteers administered the antidepressant sibutramine HCL. Psychopharmacology (1990) 100:345–349.
   PubMedGoogle Scholar
• COLE JO, LEVIN A, BEAKE B, KAISER PE, SCHEINBAUM ML: Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines. Clin. Psychopharmacol. (1998) 18:231–236.
   PubMed Web of Science ®Google Scholar
• SCHUH LM, SCHUSTER CR, HOPPER JA, MENDEL CM:Abuse liability assessment of sibutramine, a novel weight control agent. Psychopharmacology (2000)147:339–346.
   PubMed Web of Science ®Google Scholar
• BACH DS, RISSANEN AM,MENDEL CM et al.: Absence of cardiac valve dysfunction in obese patients treated with sibutramine. Obes. Res. (1999) 7:363–369.
   Google Scholar
• BOSELLO 0, CARRUBA MO, FERRANNINI E, ROTELLA CM: Sibutramine lost and found.Eat. Weight Disord. (2002) 7:161–167.
   Google Scholar
• BRAY GA, GREENWAY FL:Current and potential drugs for treatment of obesity. Endocr. Rev (1999) 20:805–875.
   PubMed Web of Science ®Google Scholar
• http://www.cdc.gov/nchs/products/pubs/pub d/hestats/obese/obse99.htmCenters for Disease Control/National Center for Health Statistics (2003a). Prevalence of overweight and obesity among adults: United States 1999— 2000. Accessed August 29, 2003.
   Google Scholar
• http://www.cdc.gov/nchs/products/pubs/pub d/hestats/overwght99.htmCenters for Disease Control/National Center for Health Statistics (20036). Prevalence of overweight and obesity among children and adolescents: United States 1999 — 2000. Accessed August 29, 2003.
   Google Scholar
• http://www.who.int/nut/obs.htm WORLD HEALTH ORGANIZATION: Controlling the global obesity epidemic. Accessed August 29, 2003.
   Google Scholar